ILMN

In the past six months (approximately April to October 2026), Illumina's stock price has seen significant positive movement, increasing by 25.12% in the past month, approximately 52% over the trailing three months, 167.37% over the last 12 months, and 108.17% year-to-date. Key events impacting the stock include Q2 CY2026 results surpassing Wall Street expectations, leading to raised full-year guidance. The company's addition to the S&P 500 index, coupled with analyst upgrades and sustained clinical sequencing demand, fueled a rally. In early October 2026, shares jumped after analysts raised price targets, partly due to an expected improvement in clinical sales and the perception of its gene-sequencing technology as foundational for AI applications. In August 2026, an SVP sold 1,033 shares of the company's stock.